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Introduction
The term transient neurologic symptoms TNS is used to describe the symptoms of aches following radiation or dysesthesia in the buttocks or lower extremities 1 . TNS have been reported after spinal anesthesia with all local anesthetics. The incidence of TNS after lidocaine, for example, has been reported to be as high as 40% 2 . Several studies have shown that bupivacaine, which is currently the most commonly used local anesthetic for spinal anesthesia, is associated with lower neurotoxicity and a lower incidence of TNS 0%-3% compared with other local anesthetics 2 4 . JJSCA Vol.33 No.3, 421 -427, 2013 Incidence of Transient Neurologic Symptoms after Spinal Anesthesia： A Comparative Study between 0.24% Dibucaine/ 0.12% T-caine Compound and 0.5% Bupivacaine
Dibucaine is not used in Europe and America because of reported potent neurotoxicity 5 . However, it has long been used for spinal anesthesia in Japan because of its potency of nerve blockade 6 . Dibucaine is associated with late onset of anesthetic effects. To expedite its effects in clinical settings, 0.24% dibucaine to which T-caine is added Neo-Percamin ® S has been used more frequently to deliver spinal anesthesia compared with 0.3% dibucaine.
Although several cases of cauda equine syndrome have been reported following spinal anesthesia with dibucaine 7 , no case reports or prospective studies concerning the incidence of TNS in similar settings have been documented to date. Therefore, this study aimed to evaluate the incidence of TNS following spinal anesthesia with 0.24% dibucaine/0.12% T-caine compound Neo-Percamin ® S and compare it with that following spinal anesthesia with 0.5% bupivacaine.
Methods
The covering from 4 to 0, where 0 = able to move hip, knee, ankle, and toes 1 = unable to move hip but able to move knee, ankle and toes 2 = unable to move hip and knee but able to move ankle and toes 3 = unable to move hip, knee and ankle but able to move toes and 4 = unable to move hip, knee, ankle, and toes. The date of TNS occurrence was recorded.
Neurological examinations were performed on all symptomatic patients, and they were observed until they were symptom-free. The patients were also asked to rate the degree of discomfort using a visual analog scale 0 = no pain, 10 = worst conceivable pain .
The results are expressed as mean standard de- 
Results
Demographic data and relevant aspects of the anesthetic and surgical procedures are summarized in Table 1 . Demographic data, except for sex, did not differ significantly between the study groups. Anesthetic volume and dose are shown in Table 2 . Satisfactor y anesthesia was achieved and the operative course was uneventful in all patients. Complete recovery from anesthesia by the night of surgery was documented in all patients.
The incidence and characteristics of TNS are presented in Table 3 . Symptoms were obser ved in 4 patients 8% who received dibucaine/T-caine compound and 5 patients 10% who received bupivacaine. Demographics and perioperative characteristics did not differ between patients with and without TNS.
Discussion
The present study found no significant difference in the incidence of TNS between patients given dibu- Values indicate the number of patients.
Pain intensity was rated according to a visual analog scale 0 = no pain, 10 = worst conceivable pain .
There were no significant differences between the two groups.
derivative of tetracaine, its anesthetic effects have been considered to be nearly the same as those of tetracaine. Ogawa et al. 11 showed that dibucaine, tetracaine and bupivacaine concentrations that caused irreversible blockade of type-C ner ve fibers were 0.03%, 0.075%, and 0.5%, respectively, in a rabbit desheathed cervical nerve model, indicating that the neurotoxicity of dibucaine and tetracaine was more than 16 and 6 times, respectively, as potent as that of bupivacaine. However, the incidence of TNS was of no significant relevance to the neurotoxic potency of the anesthetics in our study groups. In addition, another study indicated no significant difference in the incidence of TNS after spinal anesthesia between prilocaine and bupivacaine, despite differences in their neurotoxic potency 4 . Therefore, the etiology of Although the etiology of TNS remains to be determined, it is likely that differences in the incidence of TNS are due partly to an intrinsic property of the anesthetics based on the findings of the studies discussed above and the present study.
Several studies have reported a low incidence of TNS with bupivacaine spinal anesthesia 0%-3% 2 , 4 .
Surprisingly, the incidence of TNS following bupivacaine spinal anesthesia was much higher 10% in the present study. This may have been because we de- In the present study, the discomfort of TNS was relatively minor on a 10-point visual analog scale, the median values for symptomatic patients were 2.0 for dibucaine/T-caine compound and 2.5 for bupivacaine. The symptoms also resolved spontaneously or were treated effectively with potent nonsteroidal anti-inflammatory drugs. No patient had a sensory or motor deficit. Therefore, TNS only had a minimal impact on the patients postoperative course in the present study. However, we cannot conclude from these findings that serious neurological injury will not develop after spinal anesthesia. Accountability for perioperative anesthetic management in patients has been considered an important issue in recent years.
The risk of TNS such as pain or dysesthesia in the buttocks or lower extremities and the possibility of serious neurological injury, albeit with a low frequency, must be sufficiently explained to patients prior to spinal anesthesia and surgery.
Our study had several limitations. First, the number of patients studied was small. Accordingly, a larger follow-up study may be required to confirm these findings. Second, the anesthetists administering the spinal blocks were not blinded to the anesthetics used. Therefore, bias cannot be excluded. However, the research anesthetists who contacted and evaluated patients after surgery were blinded to all aspects of anesthetic care. Third, because we used the compound of dibucaine and T-caine, the anesthetic potencies of dibucaine and bupivacaine which were used were not equal. Strictly speaking, the anesthetic potencies must be the same in comparison with its neurotoxicity. Therefore, 0.3% dibucaine should be used for future research when compared with 0.5% bupivacaine.
In conclusion, the present results suggest no significant difference in the incidence of TNS between patients given dibucaine/T-caine spinal anesthesia and those given bupivacaine spinal anesthesia. The relationship between the neurotoxic potency of anesthetics and the incidence of TNS remains speculative.
Further large-scale studies will be required to confirm these findings.
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